Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics in the Bear Market: How are Public Companies Doing?

Premium

With the sharp downturn in the financial markets, BioInform decided to take a look at how bioinformatics stocks were faring. Unfortunately, the news isn’t good. Shares of all five of the bioinformatics companies that went public in 2000 are currently trading below the closing price on their first day of trading.

Of course, these companies still have something to smile about — they’ve got loads of IPO cash in the bank. Other bioinformatics companies such as DoubleTwist and NetGenics have withdrawn their offerings and undergone layoffs as they try to ride out the storm as privately held companies.

File Attachments

Filed under

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.